Now let me search for calibration anchors.Now I have enough information to write the final consolidated review. Let me synthesize:---

## Summary
This paper proposes a two-stage fine-tuning method for molecular generative LLMs to autoregressively produce structurally diverse molecule sets from a single text prompt. The two stages are: (1) supervised fine-tuning (Div-SFT) that repurposes LLMs to generate a concatenated sequence of molecules, and (2) reinforcement learning (Div-SFT+RL) with a multi-stage formulation that resolves the credit assignment problem in sequence-level diversity optimization. The method shows large gains over decoding baselines and state-of-the-art LLMs on both ChEBI-20 and DrugAssist evaluations.

---

## Strengths

- **Diagnosis of textual vs. molecular diversity mismatch (Figure 3b)**: The paper provides direct evidence that diverse beam search improves textual diversity (J-distinct) without improving molecular structural diversity, robustly motivating the need for a fine-tuning approach. This is a concrete and useful empirical finding.

- **Multi-stage RL formulation validated by ablation (Table 4)**: Decomposing the K-molecule generation task into K individual RL stages is well-motivated. Table 4 directly validates this design: multi-stage RL achieves NCircles₀.₆₅ = 14.35 vs. single-stage RL at 6.49 — a ~2.2× improvement — confirming that the credit assignment solution is the key factor.

- **Large, consistent gains over comprehensive baselines (Table 2, Figure 5)**: The method more than doubles NCircles vs. the best specialist baseline (BioT5⁺: 6.16 → 14.35). Comparisons span chemical-task specialists, fine-tuned generalists, and frontier API LLMs (GPT-3.5, GPT-4o, o1-preview), making the superiority claim robust.

- **Generalization to unseen properties (Figure 7d)**: QED-based prompts are explicitly excluded from training yet the fine-tuned DrugAssist model performs strongly on them, demonstrating that the learned diversity behavior transfers rather than memorizes training distributions.

- **Self-improvement design requiring no external datasets**: Both the SFT and RL stages train on self-generated data, making the approach broadly practical. The hard-filtering ablation (Div-SFT_hard, NCircles₀.₆₅ = 6.15) demonstrates that RL exploration provides diversity gains that data curation alone cannot.

---

## Weaknesses

### Fatal
None.

### Major

- **ChEBI-20 benchmark mismatch with the diversity objective**: ChEBI-20 was designed for 1-to-1 molecule generation — each description paired with a single reference compound. The paper itself acknowledges this in the conclusion: *"ChEBI-20 datasets were originally designed for a single molecular generation."* When descriptions are maximally specific (e.g., "the conjugate acid of streothricin F" as in Table 1), there is no natural ground truth for "50 diverse molecules satisfying this description." The acceptance criterion of BLEU > 0.7 against the single reference SMILES provides a soft relaxation, but the scientific meaning of NCircles in this regime — "how many diverse molecules genuinely satisfy the description" — is undermined for highly specific descriptions. The DrugAssist experiment (Section 4.3), where property-based prompts (HB donors/acceptors, Bertz complexity) define a legitimate class of solutions, is a much cleaner evaluation, but it remains a secondary experiment while all primary quantitative comparisons (Tables 1–4) rest on ChEBI-20. Elevating the DrugAssist-style evaluation to a primary role, or validating that ChEBI-20 descriptions are mostly class-level (not compound-specific), is needed to make the headline claims fully credible.

- **BLEU-based acceptance in both the evaluation metric and the RL reward**: The description-matching reward $r_\text{match}$ is implemented as BLEU between a generated SMILES string and the reference SMILES (footnote 6; Section 4.1). The paper correctly identifies in the introduction (Figure 3b) that SMILES textual similarity ≠ molecular structural similarity. Yet the RL reward explicitly trains the model to find SMILES strings that are textually proximate to the reference, while simultaneously being structurally diverse from each other. This creates a tension: the model is incentivized to generate SMILES sharing subsequences with a specific reference — a textual criterion — while the paper's stated goal is structural property matching. The paper acknowledges this limitation in footnote 6 and notes experiments in Appendix D.2 with Tanimoto/Dice-based acceptance, but these remain secondary. Since BLEU-based acceptance underlies all of Tables 1–4, its validity as a proxy for "satisfying the description" is unverified in the main paper and is a meaningful concern for interpreting the headline results.

### Minor

- **Evaluation subset size mismatch between Section 4.1 and 4.2**: Section 4.1 evaluates on all 3,300 ChEBI-20 test descriptions while Section 4.2 uses only the first 500 descriptions (without explanation). Since both sections compare methods on the same BioT5⁺ base model, readers cannot directly compare the numbers across sections, and there is no verification that the first-500 subset is representative.

- **Reward coefficient sensitivity not analyzed**: $\lambda_\text{div} = \lambda_\text{match} = 1$ is set without ablation (Section 3.2). Given the structural tension between these two rewards (diversity pushes molecules away from the reference; description-matching pulls toward it), the ratio is a critical hyperparameter whose effect on the diversity–quality trade-off is unknown.

- **SFT-only baseline not given diverse decoding in Section 4.1**: The decoding baselines (diverse beam search, contrastive beam search, nucleus sampling) are applied to the non-fine-tuned BioT5⁺/MolT5. Div-SFT appears in Figure 5, but applying diverse decoding schemes to Div-SFT (without RL) would isolate whether RL specifically drives diversity improvement or whether the SFT reformulation alone, combined with better decoding, achieves similar gains. This ablation is missing.

- **Div-SFT_hard ablation has a potential dataset-size confound (Table 4)**: Hard-filtering by Tanimoto < 0.65 may substantially reduce the training set size relative to Div-SFT. The paper does not report effective dataset sizes. This confounds whether Div-SFT_hard performs worse because of the filtering criterion or simply because it trains on fewer examples.

### Trivial

- The paper claims "we are the first to explore the use of LLMs for generating diverse molecules" (Introduction, bullet 1) — this is accurate but could be phrased more precisely as "the first to apply RL-based fine-tuning of LLMs to the structural diversity objective" to avoid potential overclaiming.

---

## Nice-to-Haves

- **Promote DrugAssist-style evaluation to primary**: The property-based acceptance criterion (property satisfaction) used in Section 4.3 is semantically grounded in a way BLEU is not. Quantifying NCircles and IntDiv on DrugAssist-style tasks as the primary experiment — alongside ChEBI-20 for comparison with prior work — would resolve the benchmark-mismatch concern and make the headline claims fully credible.

- **Scaffold diversity analysis**: Tanimoto fingerprint diversity can reflect peripheral substituent variation on shared scaffolds. Reporting Bemis-Murcko scaffold diversity alongside Tanimoto-based metrics would validate that the generated molecules are genuinely structurally diverse rather than variants of a common core.

- **Qualitative analysis of "accepted" molecules for specific descriptions**: Showing the actual structures (not just SMILES strings) of the 14–17 NCircles-counted molecules for a specific ChEBI-20 description would provide direct evidence that they are chemically meaningful and related to the described class, rather than SMILES strings that happen to score BLEU > 0.7.

- **Reward coefficient ($\lambda_\text{div}/\lambda_\text{match}$) sensitivity analysis**: A sweep over this ratio would characterize the diversity–quality trade-off curve, helping practitioners understand the design space.

---

## Removed Points

*These points are flagged to be removed — treat them with caution.*

- **Harsh Critic Claim — Efficiency comparison is unfair (mismatched compute)**: The paper explicitly states beam search requires 4 GPUs "due to the memory limitation of a single GPU" — this is a hardware constraint, not an arbitrary choice. With 4 GPUs, beam search at 300 samples takes 323 seconds; the proposed method takes 65 seconds on 1 GPU. On a single GPU, beam search would take ~4× longer (~1292 seconds), making the proposed method's efficiency advantage even larger than shown. The harsh critic's framing reverses the direction of the asymmetry: the 4-GPU setup actually gives beam search a wall-clock advantage, so the comparison is conservative in favor of beam search. **Removed because the criticism is factually incorrect about which direction the asymmetry cuts.**

- **Strength Finder — "Superior efficiency via fewer generations"**: While the number-of-generations comparison is valid (85 vs. 300–500 for similar NCircles), the "lower compute cost" claim deserves the nuance above. The core efficiency claim holds but the GPU-count asymmetry should be flagged. **Kept in attenuated form; pure "lower time and compute" framing removed from Strengths as it overstates a more subtle point.**

- **Harsh Critic — "First contribution claim is too strong"**: The paper's footnote 3 explicitly says "to the best of our knowledge, there exist no prior RL-based approaches that aim to increase the diversity of LLM-generated outputs." This is a narrowly scoped claim and is adequately qualified. **Removed as addressed by the paper.**

---

## Novel Insights

The paper's most genuinely novel observation is the empirical demonstration that text-level diversity improvements (Figure 3b, diverse beam search → higher J-distinct in SMILES) systematically fail to translate to molecular structural diversity, and that this failure persists across the full ChEBI-20 test set. This decoupling of textual and structural diversity in molecular SMILES is a concrete, reproducible finding that is useful to the field regardless of the paper's proposed solution. The multi-stage RL decomposition (Algorithm 2) is also a technically clean solution to the credit assignment problem in set-valued generation tasks, and the empirical gap between single-stage (NCircles=6.49) and multi-stage RL (NCircles=14.35) provides unusually clear support for this design principle.

---

## Suggestions

1. **Reprioritize evaluation**: Make property-based (DrugAssist-style) acceptance criteria the primary quantitative evaluation. Retain ChEBI-20 for backward comparability with BioT5⁺ and MolT5 baselines, but present it as a secondary result with the acknowledged benchmark-mismatch caveat prominent in the main text rather than relegated to the conclusion.

2. **Replace BLEU reward with Tanimoto/Dice in main experiments**: Appendix D.2 already does this — move it to the main paper or at least report both metrics side by side in Table 2 and Table 4, so readers can verify the gains are not BLEU-metric artifacts.

3. **Validate accepted molecules qualitatively**: For at least one ChEBI-20 description, show the chemical structures of all accepted molecules, their actual Tanimoto similarity to the reference, and whether they plausibly belong to the described class.

4. **Add diverse-decoding on Div-SFT ablation**: Apply diverse beam search to Div-SFT (not just to the pretrained model) to determine whether RL adds value beyond the SFT reformulation alone.

---

## Score and Decision

**Calibration anchors:**

| Paper | Avg Score | Relevance |
|---|---|---|
| RLDV (RL for drug design, dynamic vocab) | 3.0 | Same domain; far weaker contribution — no novel insight, outdated baselines |
| "Exploring Recall of LMs: Molecules" | 4.4 | Similar evaluation design concern (benchmark mismatch); weaker technical contribution |
| Small Molecule Optimization with LLMs | 5.75 | Similar profile: solid empirical results, solid methodology, evaluation concerns; rejected |
| Domain-Agnostic MolGen | 7.0 | Accepted poster; comparable empirical strength; cleaner evaluation |
| SynFlowNet | 7.5 | Accepted Spotlight; stronger novelty and cleaner evaluation; multi-objective molecular diversity |

The paper under review is clearly above RLDV (3.0) and "Recall of LMs" (4.4) — it has a more technically original contribution, stronger baselines, and better ablations. Versus the Small Molecule Optimization paper (5.75, rejected): our paper has more novel insight (multi-stage RL credit assignment) and more comprehensive baselines, but shares a similarly real evaluation concern (benchmark mismatch, questionable acceptance metric). Versus Domain-Agnostic MolGen (7.0) and SynFlowNet (7.5): those papers have cleaner, purpose-built evaluations and stronger technical foundations without acknowledged metric flaws in their primary experiments.

The paper sits between the 5.75 and 7.0 anchors. The multi-stage RL contribution and the DrugAssist generalization results push it toward the 7.0 anchor; the unresolved BLEU/ChEBI-20 concern in the primary experiments and the missing ablations pull it back toward 5.75. The fact that the paper itself acknowledges the benchmark mismatch in its own conclusion — while not resolving it in the primary evaluation — is a meaningful signal that the authors know the core evaluation is suboptimal. I place it at **5.5**, slightly below the accept threshold.

**Overall Assessment**: The paper makes a genuine and technically sound contribution to the problem of diverse molecular generation with LLMs. The multi-stage RL formulation is well-motivated and strongly validated by ablation. However, the primary evaluation rests on a benchmark and acceptance criterion that the paper itself flags as ill-suited to the diversity task. The DrugAssist experiment (Section 4.3) provides a more rigorous validation but is not comprehensive enough to carry the primary quantitative claims. This is a borderline paper that would likely be acceptable with a revision that makes property-based evaluation primary and demonstrates results under structurally grounded acceptance criteria in the main paper.

**Score: 5.5 | Decision: Reject (borderline)**

MY FINAL SCORE: <pineapple>5.5</pineapple>
MY FINAL DECISION: <orange>Reject</orange>